Uveitis Market, Size, Share, Trends, Epidemiology Forecast till 2030

July 24 16:06 2020
Uveitis Market, Size, Share, Trends, Epidemiology Forecast till 2030

DelveInsight Business Research LLP
DelveInsight’s “Uveitis Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Uveitis, historical and forecasted epidemiology as well as the Uveitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Uveitis market report provides current treatment practices, emerging drugs, Uveitis market share of the individual therapies, current and forecasted Uveitis market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Uveitis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

 Key benefits of the report
1. Uveitis market report covers a descriptive overview and comprehensive insight of the Uveitis epidemiology and Uveitis market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Uveitis market report provides insights on the current and emerging therapies.
3. Uveitis market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Uveitis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Uveitis market.

Request for sample pages

Amongst the therapeutic class, the Corticosteroids are believed to hold the highest patient share [%] amongst the other therapeutic options available for the Uveitis treatment.

Uveitis has been demonstrated to cause less than 50% of cases of legal blindness in the United States and the European Union and up to 25% of cases of legal blindness in developing countries. Several drugs are available for the management of noninfectious Uveitis including corticosteroids, immunosuppressive agents, and more recently, biologics.

The use of corticosteroids is recommended as first-line therapy for patients with active Uveitis. However, long-term corticosteroid treatment can cause severe systemic and ocular side effects, such as hypertension, diabetes, cataract, and glaucoma. In Uveitis, corticosteroids can be used topically, particularly, intraocularly, or systemically. Local corticosteroids have an efficacy mainly on anterior Uveitis, with reduced efficacy on the posterior segment of the eye. Corticosteroids are associated with multiple ocular complications, such as ocular hypertension in steroid responder patients.

Table of contents
1. Key Insight

2. Uveitis Market Overview at a Glance

3. Uveitis Disease Background and Overview

4. Uveitis Epidemiology and Patient Population

5. United States-Epidemiology of Uveitis

5.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location

6. EU-5 Epidemiology of Uveitis

6.1. Germany

6.2. France

6.3. Italy

6.4. Spain

6.5. United Kingdom

7. Japan

8. Uveitis Treatment

9. Unmet Needs

10. Uveitis Marketed Drugs

10.2. Durezol: Sirion Therapeutics

10.3. Triesence: Novartis

10.4. Retisert: Valeant Pharmaceuticals International Inc

10.5. Ozurdex: Allergan plc

10.6. Humira: AbbVie Inc.

10.7. Yutiq: Eyepoint Pharmaceuticals

10.8. Tobradex: Alcon Laboratories

10.9. Acthar: Mallinckrodt

10.10. Iluvien: Alimera Sciences

11. Uveitis Emerging Drugs Analysis

11.1. Key Cross Competition

11.2. ADX-102: Aldeyra Therapeutics Inc.

11.3. Sirolimus: Santen

11.3.6. Product Profile

11.4. EGP-437: EyeGate Pharmaceuticals

11.5. Suprachoroidal CLS-TA: Clearside Biomedical, Inc.

11.6. Sarilumab: Sanofi Aventis

12. Uveitis 7 Major Market Analysis

13. United States: Market Outlook

14. EU5: Market Outlook

14.1. Germany Market Size

14.2. France Market Size

14.3. Italy Market Size

14.4. Spain Market Size

14.5. United Kingdom Market Size

15. Japan: Market Outlook

16. Market Drivers

17. Market Barriers

18. Appendix

19. Uveitis Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

 

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/haridwartoday/goaheadlines.org/wp-content/themes/gadgetine-theme/includes/single/post-tags-categories.php on line 7